
BIBLIOGRAFIA

A

- Adams JM, Harris AW, Strasser A, Ogilvy S and Cory S (1999) Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector. *Oncogene* 18:5268-77.
- Aguayo C, Casado J, Gonzalez M, Pearson JD, Martin RS, Casanello P, Pastor-Anglada M and Sobrevia L (2005) Equilibrative nucleoside transporter 2 is expressed in human umbilical vein endothelium, but is not involved in the inhibition of adenosine transport induced by hyperglycaemia. *Placenta* 26:641-53.
- Albertioni F, Lindemalm S, Reichelova V, Pettersson B, Eriksson S, Juliusson G and Liliemark J (1998) Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. *Clin Cancer Res* 4:653-8.
- Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Jr., Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO and Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature* 403:503-11.
- Alvarado Y, Kantarjian HM, Cortes JE, Apostolidou E, Bivins C and Giles FJ (2002) Troxacitabine activity in extramedullary myeloid leukemia. *Hematology* 7:179-85.
- Anderson CM, Xiong W, Young JD, Cass CE and Parkinson FE (1996) Demonstration of the existence of mRNAs encoding N1/cif and N2/cit sodium/nucleoside cotransporters in rat brain. *Brain Res Mol Brain Res* 42:358-61.
- Aran JM and Plagemann PG (1992) Nucleoside transport-deficient mutants of PK-15 pig kidney cell line. *Biochim Biophys Acta* 1110:51-8.
- Arner ES and Eriksson S (1995) Mammalian deoxyribonucleoside kinases. *Pharmacol Ther* 67:155-86.
- Arner ES, Flygar M, Bohman C, Wallstrom B and Eriksson S (1988) Deoxycytidine kinase is constitutively expressed in human lymphocytes: consequences for compartmentation effects, unscheduled DNA synthesis, and viral replication in resting cells. *Exp Cell Res* 178:335-42.
- Arner ES, Spasokoukotskaja T, Juliusson G, Liliemark J and Eriksson S (1994) Phosphorylation of 2-chlorodeoxyadenosine (CdA) in extracts of peripheral blood mononuclear cells of leukaemic patients. *Br J Haematol* 87:715-8.
- Ashkenazi A (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. *Nat Rev Cancer* 2:420-30.
- Avramis VI, Wiersma S, Krailo MD, Ramilo-Torno LV, Sharpe A, Liu-Mares W, Kowck R, Reaman GH and Sato JK (1998) Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. *Clin Cancer Res* 4:45-52.
- Aymerich I, Duflot S, Fernandez-Veledo S, Guillen-Gomez E, Huber-Ruano I, Casado FJ and Pastor-Anglada M (2005) The concentrative nucleoside transporter family (SLC28): new roles beyond salvage? *Biochem Soc Trans* 33:216-9.
- Aymerich I, Pastor-Anglada M and Casado FJ (2004) Long term endocrine regulation of nucleoside transporters in rat intestinal epithelial cells. *J Gen Physiol* 124:505-12.

B

- Backus HH, Pinedo HM, Wouters D, Kuiper CM, Jansen G, van Groeningen CJ and Peters GJ (2000) Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates. *Oncol Res* 12:231-9.
- Badagnani I, Chan W, Castro RA, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Ferrin TE, Carlson EJ, Burchard EG and Giacomini KM (2005) Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). *Pharmacogenomics* 5:157-65.
- Bai L, Yamaguchi M, Tatsumi M, Kon K and Brautigam M (1998) Mechanisms responsible for resistance of sublines derived from leukemia cell lines to an antitumor agent 9-beta-D-arabinofuranosyl-2-fluoroadenine. *J Cancer Res Clin Oncol* 124:367-73.

- Baldwin SA, Beal PR, Yao SY, King AE, Cass CE and Young JD (2004) The equilibrative nucleoside transporter family, SLC29. *Pflugers Arch* 447:735-43.
- Baldwin SA, Mackey JR, Cass CE and Young JD (1999) Nucleoside transporters: molecular biology and implications for therapeutic development. *Mol Med Today* 5:216-24.
- Baldwin SA, Yao SY, Hyde RJ, Ng AM, Foppolo S, Barnes K, Ritzel MW, Cass CE and Young JD (2005) Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. *J Biol Chem* 280:15880-7.
- Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y and Ziv Y (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. *Science* 281:1674-7.
- Barak Y, Juven T, Haffner R and Oren M (1993) mdm2 expression is induced by wild type p53 activity. *Embo J* 12:461-8.
- Belt JA, Harper EH, Byl JA and Noel LA (1992) Sodium-dependent nucleoside transport in human myeloid leukemic cell lines and freshly isolated myeloblast. *Proc Am Assoc Cancer Res* 22, 20.
- Belt JA, Marina NM, Phelps DA and Crawford CR (1993) Nucleoside transport in normal and neoplastic cells. *Adv Enzyme Regul* 33:235-52.
- Bertoni F, Zucca E and Cotter FE (2004) Molecular basis of mantle cell lymphoma. *Br J Haematol* 124:130-40.
- Beutler E (1992) Cladribine (2-chlorodeoxyadenosine). *Lancet* 340:952-6.
- Bhalla K, Nayak R and Grant S (1984) Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D-arabinofuranosylcytosine. *Cancer Res* 44:5029-37.
- Binet JL, Auquier A, Dighiero G, Chastang C, Piguët H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbès S and Gremy F (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. *Cancer* 48:198-206.
- Biswal SS, Datta K, Acquaaah-Mensah GK and Kehrer JP (2000) Changes in ceramide and sphingomyelin following fludarabine treatment of human chronic B-cell leukemia cells. *Toxicology* 154:45-53.
- Borst P and Elferink RO (2002) Mammalian ABC transporters in health and disease. *Annu Rev Biochem* 71:537-92.
- Bosch F, Ferrer A, Lopez-Guillermo A, Gine E, Bellosillo B, Villamor N, Colomer D, Cobo F, Perales M, Esteve J, Altes A, Besalduch J, Ribera JM and Montserrat E (2002) Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. *Br J Haematol* 119:976-84.
- Boyum A (1964) Separation of White Blood Cells. *Nature* 204:793-4.
- Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 72:248-54.
- Brockman RW, Schabel FM, Jr. and Montgomery JA (1977) Biologic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-beta-D-arabinofuranosyladenine. *Biochem Pharmacol* 26:2193-6.
- Brown NC and Reichard P (1969) Role of effector binding in allosteric control of ribonucleoside diphosphate reductase. *J Mol Biol* 46:39-55.
- Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, Kallioniemi A, Fornace AJ, Jr. and Appella E (2002) Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. *Nat Genet* 31:210-5.
- Burnette WN (1981) "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. *Anal Biochem* 112:195-203.
- Byrd JC, Rai KR, Sausville EA and Grever MR (1998) Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals. *Semin Oncol* 25:65-74.

C

- Campo E (2003) Genetic and molecular genetic studies in the diagnosis of B-cell lymphomas I: mantle cell lymphoma, follicular lymphoma, and Burkitt's lymphoma. *Hum Pathol* 34:330-5.
- Cano-Soldado P, Lorrayo IM, Molina-Arcas M, Casado FJ, Martinez-Picado J, Lostao MP and Pastor-Anglada M (2004) Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1). *Antivir Ther* 9:993-1002.
- Cao TM and Coutre SE (2003) Management of advanced chronic lymphocytic leukemia. *Curr Hematol Rep* 2:65-72.
- Capello D and Gaidano G (2000) Molecular pathophysiology of indolent lymphoma. *Haematologica* 85:195-201.
- Caras IW and Martin DW, Jr. (1988) Molecular cloning of the cDNA for a mutant mouse ribonucleotide reductase M1 that produces a dominant mutator phenotype in mammalian cells. *Mol Cell Biol* 8:2698-704.
- Cass CE, Dahlig E, Lau EY, Lynch TP and Paterson AR (1979) Fluctuations in nucleoside uptake and binding of the inhibitor of nucleoside transport, nitrobenzylthioinosine, during the replication cycle of HeLa cells. *Cancer Res* 39:1245-52.
- Chan JK (2001) The new World Health Organization classification of lymphomas: the past, the present and the future. *Hematol Oncol* 19:129-50.
- Chan TC (1989) Augmentation of 1-beta-D-arabinofuranosylcytosine cytotoxicity in human tumor cells by inhibiting drug efflux. *Cancer Res* 49:2656-60.
- Chandrasena G, Giltay R, Patil SD, Bakken A and Unadkat JD (1997) Functional expression of human intestinal Na⁺-dependent and Na⁺-independent nucleoside transporters in *Xenopus laevis* oocytes. *Biochem Pharmacol* 53:1909-18.
- Chang C, Swaan PW, Ngo LY, Lum PY, Patil SD and Unadkat JD (2004) Molecular requirements of the human nucleoside transporters hCNT1, hCNT2, and hENT1. *Mol Pharmacol* 65:558-70.
- Chau I, Harries M, Cunningham D, Hill M, Ross PJ, Archer CD, Norman AR, Wotherspoon A, Koh DM, Gill K, Uzzell M, Prior Y and Catovsky D (2003) Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. *Br J Haematol* 120:970-7.
- Che M, Ortiz DF and Arias IM (1995) Primary structure and functional expression of a cDNA encoding the bile canalicular, purine-specific Na⁽⁺⁾-nucleoside cotransporter. *J Biol Chem* 270:13596-9.
- Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A and Kipps TJ (2002) Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. *Blood* 100:4609-14.
- Chen SF, Stoeckler JD and Parks RE, Jr. (1984) Transport of deoxycoformycin in human erythrocytes. Measurement by adenosine deaminase titration and radioisotope assays. *Biochem Pharmacol* 33:4069-79.
- Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K₁) and the concentration of inhibitor which causes 50 per cent inhibition (IC₅₀) of an enzymatic reaction. *Biochem Pharmacol* 22:3099-108.
- Chiorazzi N, Rai KR and Ferrarini M (2005) Chronic lymphocytic leukemia. *N Engl J Med* 352:804-15.
- Choi DS, Cascini MG, Mailliard W, Young H, Paredes P, McMahon T, Diamond I, Bonci A and Messing RO (2004) The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference. *Nat Neurosci* 7:855-61.
- Chomczynski P and Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 162:156-9.
- Chow L, Lai R, Dabbagh L, Belch A, Young JD, Cass CE and Mackey JR (2005) Analysis of human equilibrative nucleoside transporter 1 (hENT1) protein in non-Hodgkin's lymphoma by immunohistochemistry. *Mod Pathol* 18:558-64.
- Ciccolini J, Fina F, Bezulier K, Giacometti S, Roussel M, Evrard A, Cuq P, Romain S, Martin PM and Aubert C (2002) Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas. *Mol Cancer Ther* 1:923-7.
- Coe I, Zhang Y, McKenzie T and Naydenova Z (2002) PKC regulation of the human equilibrative nucleoside transporter, hENT1. *FEBS Lett* 517:201-5.

- Coe IR, Griffiths M, Young JD, Baldwin SA and Cass CE (1997) Assignment of the human equilibrative nucleoside transporter (hENT1) to 6p21.1-p21.2. *Genomics* 45:459-60.
- Cohen A, Lee JW and Gelfand EW (1983) Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. *Blood* 61:660-6.
- Cohen BJ, Moskowitz C, Straus D, Noy A, Hedrick E and Zelenetz A (2001) Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. *Leuk Lymphoma* 42:1015-22.
- Cory S and Adams JM (2002) The Bcl2 family: regulators of the cellular life-or-death switch. *Nat Rev Cancer* 2:647-56.
- Crawford CR, Cass CE, Young JD and Belt JA (1998a) Stable expression of a recombinant sodium-dependent, pyrimidine-selective nucleoside transporter (CNT1) in a transport-deficient mouse leukemia cell line. *Biochem Cell Biol* 76:843-51.
- Crawford CR, Ng CY, Noel LD and Belt JA (1990) Nucleoside transport in L1210 murine leukemia cells. Evidence for three transporters. *J Biol Chem* 265:9732-6.
- Crawford CR, Patel DH, Naeve C and Belt JA (1998b) Cloning of the human equilibrative, nitrobenzylmercaptapurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line. *J Biol Chem* 273:5288-93.
- Curbo S, Zhu C, Johansson M, Balzarini J and Karlsson A (2001) Dual mechanisms of 9-beta-D-arabinofuranosylguanine resistance in CEM T-lymphoblast leukemia cells. *Biochem Biophys Res Commun* 285:40-5.

D

- Dabbagh L, Coupland RW, Cass CE and Mackey JR (2003) Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. *Clin Cancer Res* 9:3213-4.
- Dagnino L and Paterson AR (1990) Sodium-dependent and equilibrative nucleoside transport systems in L1210 mouse leukemia cells: effect of inhibitors of equilibrative systems on the content and retention of nucleosides. *Cancer Res* 50:6549-53.
- Damaraju S, Zhang J, Visser F, Tackaberry T, Dufour J, Smith KM, Slugoski M, Ritzel MW, Baldwin SA, Young JD and Cass CE (2005) Identification and functional characterization of variants in human concentrative nucleoside transporter 3, hCNT3 (SLC28A3), arising from single nucleotide polymorphisms in coding regions of the hCNT3 gene. *Pharmacogenet Genomics* 15:173-82.
- Decaudin D, Bosq J, Tertian G, Nedellec G, Bennaceur A, Venuat AM, Bayle C, Carde P, Bendahmane B, Hayat M and Munck JN (1998) Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. *J Clin Oncol* 16:579-83.
- del Santo B, Tarafa G, Felipe A, Casado FJ and Pastor-Anglada M (2001) Developmental regulation of the concentrative nucleoside transporters CNT1 and CNT2 in rat liver. *J Hepatol* 34:873-80.
- del Santo B, Valdes R, Mata J, Felipe A, Casado FJ and Pastor-Anglada M (1998) Differential expression and regulation of nucleoside transport systems in rat liver parenchymal and hepatoma cells. *Hepatology* 28:1504-11.
- Delicado EG, Casillas T, Sen RP and Miras-Portugal MT (1994) Evidence that adenine nucleotides modulate nucleoside-transporter function. Characterization of uridine transport in chromaffin cells and plasma membrane vesicles. *Eur J Biochem* 225:355-62.
- Diasio RB and Harris BE (1989) Clinical pharmacology of 5-fluorouracil. *Clin Pharmacokinet* 16:215-37.
- Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M and Lichter P (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med* 343:1910-6.
- Doong SL and Dolnick BJ (1988) 5-Fluorouracil substitution alters pre-mRNA splicing in vitro. *J Biol Chem* 263:4467-73.
- Dragan Y, Valdes R, Gomez-Angelats M, Felipe A, Javier Casado F, Pitot H and Pastor-Anglada M (2000) Selective loss of nucleoside carrier expression in rat hepatocarcinomas. *Hepatology* 32:239-46.

- Duflot S, Calvo M, Casado FJ, Enrich C and Pastor-Anglada M (2002) Concentrative nucleoside transporter (rCNT1) is targeted to the apical membrane through the hepatic transcytotic pathway. *Exp Cell Res* 281:77-85.
- Duflot S, Riera B, Fernandez-Veledo S, Casado V, Norman RI, Casado FJ, Lluís C, Franco R and Pastor-Anglada M (2004) ATP-sensitive K(+) channels regulate the concentrative adenosine transporter CNT2 following activation by A(1) adenosine receptors. *Mol Cell Biol* 24:2710-9.
- Dumontet C, Morschhauser F, Solal-Celigny P, Bouafia F, Bourgeois E, Thieblemont C, Leleu X, Hequet O, Salles G and Coiffier B (2001) Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. *Br J Haematol* 113:772-8.

E

- Eda H, Ura M, K FO, Tanaka Y, Miwa M and Ishitsuka H (1998) The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase. *Cancer Res* 58:1165-9.
- el-Deiry WS (1998) Regulation of p53 downstream genes. *Semin Cancer Biol* 8:345-57.
- Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D and Iacopetta B (2001) P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. *Clin Cancer Res* 7:1343-9.
- Eriksson S, Cederlund E, Bergman T, Jornvall H and Bohman C (1991) Characterization of human deoxycytidine kinase. Correlation with cDNA sequences. *FEBS Lett* 280:363-6.

F

- Fabianowska-Majewska K and Wyczechowska D (1996) 2-Chloro-2'-deoxyadenosine (2CdA) biochemical aspects of antileukemic efficacy. *Acta Pol Pharm* 53:231-9.
- Farre X, Guillen-Gomez E, Sanchez L, Hardisson D, Plaza Y, Lloberas J, Casado FJ, Palacios J and Pastor-Anglada M (2004) Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. *Int J Cancer* 112:959-66.
- Felipe A, Valdes R, Santo B, Lloberas J, Casado J and Pastor-Anglada M (1998) Na⁺-dependent nucleoside transport in liver: two different isoforms from the same gene family are expressed in liver cells. *Biochem J* 330 (Pt 2):997-1001.
- Fenaux P, Preudhomme C, Lai JL, Quiquandon I, Jonveaux P, Vanrumbeke M, Sartiaux C, Morel P, Loucheux-Lefebvre MH, Bauters F and et al. (1992) Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. *Leukemia* 6:246-50.
- Fernandez-Veledo S, Valdes R, Wallenius V, Casado FJ and Pastor-Anglada M (2004) Up-regulation of the high-affinity pyrimidine-preferring nucleoside transporter concentrative nucleoside transporter 1 by tumor necrosis factor- α and interleukin-6 in liver parenchymal cells. *J Hepatol* 41:538-44.
- Ferrer A, Marce S, Bellosillo B, Villamor N, Bosch F, Lopez-Guillermo A, Espinet B, Sole F, Montserrat E, Campo E and Colomer D (2004) Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes. *Oncogene* 23:8941-9.
- Flanagan SA, Gandhi V, Secrist JA, 3rd and Meckling KA (2003) The novel nucleoside transport system exhibited by NB4 cells, csg, transports deoxyguanosine analogues, including ara-G. *Biochem Pharmacol* 66:733-7.
- Flanagan SA and Meckling-Gill KA (1997) Characterization of a novel Na⁺-dependent, guanosine-specific, nitrobenzylthioinosine-sensitive transporter in acute promyelocytic leukemia cells. *J Biol Chem* 272:18026-32.
- Flatt PM, Polyak K, Tang LJ, Scatena CD, Westfall MD, Rubinstein LA, Yu J, Kinzler KW, Vogelstein B, Hill DE and Pietenpol JA (2000) p53-dependent expression of PIG3 during proliferation, genotoxic stress, and reversible growth arrest. *Cancer Lett* 156:63-72.

G

- Galmarini CM, Graham K, Thomas X, Calvo F, Rousselot P, El Jafaari A, Cros E, Mackey JR and Dumontet C (2001a) Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. *Blood* 98:1922-6.
- Galmarini CM, Mackey JR and Dumontet C (2001b) Nucleoside analogues: mechanisms of drug resistance and reversal strategies. *Leukemia* 15:875-90.
- Galmarini CM, Mackey JR and Dumontet C (2002a) Nucleoside analogues and nucleobases in cancer treatment. *Lancet Oncol* 3:415-24.
- Galmarini CM, Thomas X, Calvo F, Rousselot P, Jafaari AE, Cros E and Dumontet C (2002b) Potential mechanisms of resistance to cytarabine in AML patients. *Leuk Res* 26:621-9.
- Galmarini CM, Thomas X, Calvo F, Rousselot P, Rabilloud M, El Jaffari A, Cros E and Dumontet C (2002c) In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. *Br J Haematol* 117:860-8.
- Galmarini CM, Thomas X, Graham K, El Jafaari A, Cros E, Jordheim L, Mackey JR and Dumontet C (2003) Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. *Br J Haematol* 122:53-60.
- Galton DA (1966) The pathogenesis of chronic lymphocytic leukemia. *Can Med Assoc J* 94:1005-10.
- Gandhi V, Mineishi S, Huang P, Chapman AJ, Yang Y, Chen F, Nowak B, Chubb S, Hertel LW and Plunkett W (1995) Cytotoxicity, metabolism, and mechanisms of action of 2',2'-difluorodeoxyguanosine in Chinese hamster ovary cells. *Cancer Res* 55:1517-24.
- Gandhi V, Nowak B, Keating MJ and Plunkett W (1989) Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. *Blood* 74:2070-5.
- Gandhi V, Plunkett W, Rodriguez CO, Jr., Nowak BJ, Du M, Ayres M, Kisor DF, Mitchell BS, Kurtzberg J and Keating MJ (1998) Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. *J Clin Oncol* 16:3607-15.
- Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A and Pastor-Anglada M (2003) Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. *Clin Cancer Res* 9:5000-8.
- Gartenhaus RB, Wang P, Hoffman M, Janson D and Rai KR (1996) The induction of p53 and WAF1/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine. *J Mol Med* 74:143-7.
- Gasch AP, Spellman PT, Kao CM, Carmel-Harel O, Eisen MB, Storz G, Botstein D and Brown PO (2000) Genomic expression programs in the response of yeast cells to environmental changes. *Mol Biol Cell* 11:4241-57.
- Gati WP, Misra HK, Knaus EE and Wiebe LI (1984) Structural modifications at the 2'- and 3'-positions of some pyrimidine nucleosides as determinants of their interaction with the mouse erythrocyte nucleoside transporter. *Biochem Pharmacol* 33:3325-31.
- Gati WP, Paterson AR, Belch AR, Chlumecky V, Larratt LM, Mant MJ and Turner AR (1998) Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC). *Leuk Lymphoma* 32:45-54.
- Gati WP, Paterson AR, Larratt LM, Turner AR and Belch AR (1997) Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. *Blood* 90:346-53.
- Genini D, Adachi S, Chao Q, Rose DW, Carrera CJ, Cottam HB, Carson DA and Leoni LM (2000a) Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. *Blood* 96:3537-43.
- Genini D, Budihardjo I, Plunkett W, Wang X, Carrera CJ, Cottam HB, Carson DA and Leoni LM (2000b) Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. *J Biol Chem* 275:29-34.
- Goan YG, Zhou B, Hu E, Mi S and Yen Y (1999) Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. *Cancer Res* 59:4204-7.
- Gonzalo Sanz LM (1999) *Diccionario Espasa Medicina*. Ed. Espasa
- Gourdeau H, Clarke ML, Ouellet F, Mowles D, Selner M, Richard A, Lee N, Mackey JR, Young JD, Jolivet J, Lafreniere RG and Cass CE (2001) Mechanisms of uptake and resistance to

- trioxycitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. *Cancer Res* 61:7217-24.
- Gray JH, Mangravite LM, Owen RP, Urban TJ, Chan W, Carlson EJ, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE and Giacomini KM (2004a) Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. *Mol Pharmacol* 65:512-9.
- Greenberg N, Schumm DE and Webb TE (1977) Uridine kinase activities and pyrimidine nucleoside phosphorylation in fluoropyrimidine-sensitive and -resistant cell lines of the Novikoff hepatoma. *Biochem J* 164:379-87.
- Greiner TC, Moynihan MJ, Chan WC, Lytle DM, Pedersen A, Anderson JR and Weisenburger DD (1996) p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. *Blood* 87:4302-10.
- Grem JL and Fischer PH (1989) Enhancement of 5-fluorouracil's anticancer activity by dipyrindamole. *Pharmacol Ther* 40:349-71.
- Griffith DA and Jarvis SM (1996) Nucleoside and nucleobase transport systems of mammalian cells. *Biochim Biophys Acta* 1286:153-81.
- Griffiths M, Beaumont N, Yao SY, Sundaram M, Boumah CE, Davies A, Kwong FY, Coe I, Cass CE, Young JD and Baldwin SA (1997a) Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. *Nat Med* 3:89-93.
- Griffiths M, Yao SY, Abidi F, Phillips SE, Cass CE, Young JD and Baldwin SA (1997b) Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta. *Biochem J* 328 (Pt 3):739-43.
- Guillen-Gomez E, Calbet M, Casado J, de Lecea L, Soriano E, Pastor-Anglada M and Burgaya F (2004) Distribution of CNT2 and ENT1 transcripts in rat brain: selective decrease of CNT2 mRNA in the cerebral cortex of sleep-deprived rats. *J Neurochem* 90:883-93.
- Guittet O, Hakansson P, Voevodskaya N, Fridt S, Graslund A, Arakawa H, Nakamura Y and Thelander L (2001) Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. *J Biol Chem* 276:40647-51.
- Guo Y, Kotova E, Chen ZS, Lee K, Hopper-Borge E, Belinsky MG and Kruh GD (2003) MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine. *J Biol Chem* 278:29509-14.
- Gutierrez MM and Giacomini KM (1993) Substrate selectivity, potential sensitivity and stoichiometry of Na(+)-nucleoside transport in brush border membrane vesicles from human kidney. *Biochim Biophys Acta* 1149:202-8.
- Gutierrez MM and Giacomini KM (1994) Expression of a human renal sodium nucleoside cotransporter in *Xenopus laevis* oocytes. *Biochem Pharmacol* 48:2251-3.

H

- Hallek M, Schmitt B, Wilhelm M, Busch R, Krober A, Fostitsch HP, Sezer O, Herold M, Knauf W, Wendtner CM, Kuse R, Freund M, Franke A, Schriever F, Nerl C, Dohner H, Thiel E, Hiddemann W, Brittinger G and Emmerich B (2001) Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. *Br J Haematol* 114:342-8.
- Hamilton SR, Yao SY, Ingram JC, Hadden DA, Ritzel MW, Gallagher MP, Henderson PJ, Cass CE, Young JD and Baldwin SA (2001) Subcellular distribution and membrane topology of the mammalian concentrative Na⁺-nucleoside cotransporter rCNT1. *J Biol Chem* 276:27981-8.
- Hamilton SR, Yao SY, Ingram JC, Henderson PJ, Gallagher M, Cass CE, Young JD and Baldwin SA (1997) Anti-peptide antibodies as probes of the structure and subcellular distribution of the sodium-dependent nucleoside transporter rCNT1. *J Physiol. Abstract, Sheffield Meeting*.
- Han Z, Bhalla K, Pantazis P, Hendrickson EA and Wyche JH (1999) Cif (Cytochrome c efflux-inducing factor) activity is regulated by Bcl-2 and caspases and correlates with the activation of Bid. *Mol Cell Biol* 19:1381-9.
- Hanada M, Delia D, Aiello A, Stadtmauer E and Reed JC (1993) bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. *Blood* 82:1820-8.

- Hapke DM, Stegmann AP and Mitchell BS (1996) Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. *Cancer Res* 56:2343-7.
- Heinemann V, Hertel LW, Grindey GB and Plunkett W (1988) Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. *Cancer Res* 48:4024-31.
- Heinemann V, Schulz L, Issels RD and Plunkett W (1995) Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. *Semin Oncol* 22:11-8.
- Hengartner MO (2000) The biochemistry of apoptosis. *Nature* 407:770-6.
- Herrero J, Diaz-Uriarte R and Dopazo J (2003) Gene expression data preprocessing. *Bioinformatics* 19:655-6.
- Herrero J, Valencia A and Dopazo J (2001) A hierarchical unsupervised growing neural network for clustering gene expression patterns. *Bioinformatics* 17:126-36.
- Hong M, Schlichter L and Bendayan R (2001) A novel zidovudine uptake system in microglia. *J Pharmacol Exp Ther* 296:141-9.
- Houghton JA, Harwood FG and Tillman DM (1997) Thymineless death in colon carcinoma cells is mediated via fas signaling. *Proc Natl Acad Sci U S A* 94:8144-9.
- Houghton JA, Tillman DM and Harwood FG (1995) Ratio of 2'-deoxyadenosine-5'-triphosphate/thymidine-5'-triphosphate influences the commitment of human colon carcinoma cells to thymineless death. *Clin Cancer Res* 1:723-30.
- Huang P, Chubb S and Plunkett W (1990) Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. *J Biol Chem* 265:16617-25.
- Huang P, Sandoval A, Van Den Neste E, Keating MJ and Plunkett W (2000) Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. *Leukemia* 14:1405-13.
- Huang QQ, Harvey CM, Paterson AR, Cass CE and Young JD (1993) Functional expression of Na(+)-dependent nucleoside transport systems of rat intestine in isolated oocytes of *Xenopus laevis*. Demonstration that rat jejunum expresses the purine-selective system N1 (cif) and a second, novel system N3 having broad specificity for purine and pyrimidine nucleosides. *J Biol Chem* 268:20613-9.
- Huang QQ, Yao SY, Ritzel MW, Paterson AR, Cass CE and Young JD (1994) Cloning and functional expression of a complementary DNA encoding a mammalian nucleoside transport protein. *J Biol Chem* 269:17757-60.
- Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z, Reinhold WC, Papp A, Weinstein JN and Sadee W (2004) Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. *Cancer Res* 64:4294-301.
- Hunsucker SA, Spychala J and Mitchell BS (2001) Human cytosolic 5'-nucleotidase I: characterization and role in nucleoside analog resistance. *J Biol Chem* 276:10498-504.
- Hyde RJ, Cass CE, Young JD and Baldwin SA (2001) The ENT family of eukaryote nucleoside and nucleobase transporters: recent advances in the investigation of structure/function relationships and the identification of novel isoforms. *Mol Membr Biol* 18:53-63.

I

- Iwasaki H, Huang P, Keating MJ and Plunkett W (1997) Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. *Blood* 90:270-8.

J

- Jadayel DM, Lukas J, Nacheva E, Bartkova J, Stranks G, De Schouwer PJ, Lens D, Bartek J, Dyer MJ, Kruger AR and Catovsky D (1997) Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519). *Leukemia* 11:64-72.
- Jarvis SM, Martin BW and Ng AS (1985) 2-Chloroadenosine, a permeant for the nucleoside transporter. *Biochem Pharmacol* 34:3237-41.

- Jarvis SM and Young JD (1981) Extraction and partial purification of the nucleoside-transport system from human erythrocytes based on the assay of nitrobenzylthioinosine-binding activity. *Biochem J* 194:331-9.
- Jarvis SM, Young JD and Ellory JC (1980) Nucleoside transport in human erythrocytes. Apparent molecular weight of the nitrobenzylthioinosine-binding complex estimated by radiation-inactivation analysis. *Biochem J* 190:373-6.
- Jeon HJ, Kim CW, Yoshino T and Akagi T (1998) Establishment and characterization of a mantle cell lymphoma cell line. *Br J Haematol* 102:1323-6.
- Johnston JB, Daeninck P, Verburg L, Lee K, Williams G, Israels LG, Mowat MR and Begleiter A (1997) P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. *Leuk Lymphoma* 26:435-49.
- Johnston PG and Kaye S (2001) Capecitabine: a novel agent for the treatment of solid tumors. *Anticancer Drugs* 12:639-46.
- Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. *Cancer Res* 55:1407-12.
- Jordan A and Reichard P (1998) Ribonucleotide reductases. *Annu Rev Biochem* 67:71-98.

K

- Kanamaru R, Kakuta H, Sato T, Ishioka C and Wakui A (1986) The inhibitory effects of 5-fluorouracil on the metabolism of preribosomal and ribosomal RNA in L-1210 cells in vitro. *Cancer Chemother Pharmacol* 17:43-6.
- Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ and Carson DA (1993) Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. *Blood* 81:597-601.
- Kho PS, Wang Z, Zhuang L, Li Y, Chew JL, Ng HH, Liu ET and Yu Q (2004) p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. *J Biol Chem* 279:21183-92.
- Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y and Arakawa H (2003) Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. *Nat Genet* 34:440-5.
- King K, Damaraju V, Vickers M, Yao S, Lang T, Tackaberry T, Mowles D, Ng A, Young J and Cass C (2005) A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. *Mol Pharmacol*.
- Kipps TJ (2000) Chronic lymphocytic leukemia. *Curr Opin Hematol* 7:223-34.
- Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, Freedman A, Inghirami G, Cro L, Baldini L, Neri A, Califano A and Dalla-Favera R (2001) Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. *J Exp Med* 194:1625-38.
- Kong W, Engel K and Wang J (2004) Mammalian nucleoside transporters. *Curr Drug Metab* 5:63-84.
- Kouroukis CT, Belch A, Crump M, Eisenhauer E, Gascoyne RD, Meyer R, Lohmann R, Lopez P, Powers J, Turner R and Connors JM (2003) Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 21:1740-5.
- Kroep JR, van Moorsel CJ, Veerman G, Voorn DA, Schultz RM, Worzalla JF, Tanzer LR, Merriman RL, Pinedo HM and Peters GJ (1998) Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC). *Adv Exp Med Biol* 431:657-60.
- Kubbutat MH, Jones SN and Vousden KH (1997) Regulation of p53 stability by Mdm2. *Nature* 387:299-303.
- Kugawa F, Ueno A, Kawasaki M and Aoki M (2004) Evaluation of cell death caused by CDF (cyclophosphamide, doxorubicin, 5-fluorouracil) multi-drug administration in the human breast cancer cell line MCF-7. *Biol Pharm Bull* 27:392-8.
- Kurokawa H, Nishio K, Fukumoto H, Tomonari A, Suzuki T and Saijo N (1999) Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells. *Oncol Rep* 6:33-7.

L

- Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227:680-5.
- Lai Y, Bakken AH and Unadkat JD (2002) Simultaneous expression of hCNT1-CFP and hENT1-YFP in Madin-Darby canine kidney cells. Localization and vectorial transport studies. *J Biol Chem* 277:37711-7.
- Lai Y, Lee EW, Ton CC, Vijay S, Zhang H and Unadkat JD (2005) Conserved residues F316 and G476 in the concentrative nucleoside transporter 1 (hCNT1) affect guanosine sensitivity and membrane expression, respectively. *Am J Physiol Cell Physiol* 288:C39-45.
- Lajtha LG and Vane JR (1958) Dependence of bone marrow cells on the liver for purine supply. *Nature* 182:191-2.
- Lang TT, Selner M, Young JD and Cass CE (2001) Acquisition of human concentrative nucleoside transporter 2 (hcnt2) activity by gene transfer confers sensitivity to fluoropyrimidine nucleosides in drug-resistant leukemia cells. *Mol Pharmacol* 60:1143-52.
- Larrayoz IM, Casado FJ, Pastor-Anglada M and Lostao MP (2004) Electrophysiological characterization of the human Na(+)/nucleoside cotransporter 1 (hCNT1) and role of adenosine on hCNT1 function. *J Biol Chem* 279:8999-9007.
- Lee CW (1994) Decrease in equilibrative uridine transport during monocytic differentiation of HL-60 leukaemia: involvement of protein kinase C. *Biochem J* 300 (Pt 2):407-12.
- Lee CW, Sokoloski JA, Sartorelli AC and Handschumacher RE (1991) Induction of the differentiation of HL-60 cells by phorbol 12-myristate 13-acetate activates a Na(+)-dependent uridine-transport system. Involvement of protein kinase C. *Biochem J* 274 (Pt 1):85-90.
- Lenz G, Dreyling M and Hiddemann W (2004) Mantle cell lymphoma: established therapeutic options and future directions. *Ann Hematol* 83:71-7.
- Leoni LM, Chao Q, Cottam HB, Genini D, Rosenbach M, Carrera CJ, Budihardjo I, Wang X and Carson DA (1998) Induction of an apoptotic program in cell-free extracts by 2-chloro-2'-deoxyadenosine 5'-triphosphate and cytochrome c. *Proc Natl Acad Sci U S A* 95:9567-71.
- Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. *Cell* 91:479-89.
- Liang Y, Yan C and Schor NF (2001) Apoptosis in the absence of caspase 3. *Oncogene* 20:6570-8.
- Liu G and Chen X (2002) The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis. *Oncogene* 21:7195-204.
- Loewen SK, Ng AM, Yao SY, Cass CE, Baldwin SA and Young JD (1999) Identification of amino acid residues responsible for the pyrimidine and purine nucleoside specificities of human concentrative Na(+)-nucleoside cotransporters hCNT1 and hCNT2. *J Biol Chem* 274:24475-84.
- Lomo J, Smeland EB, Krajewski S, Reed JC and Blomhoff HK (1996) Expression of the Bcl-2 homologue Mcl-1 correlates with survival of peripheral blood B lymphocytes. *Cancer Res* 56:40-3.
- Longley DB, Allen WL, McDermott U, Wilson TR, Latif T, Boyer J, Lynch M and Johnston PG (2004) The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites. *Clin Cancer Res* 10:3562-71.
- Longley DB, Boyer J, Allen WL, Latif T, Ferguson PR, Maxwell PJ, McDermott U, Lynch M, Harkin DP and Johnston PG (2002) The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. *Cancer Res* 62:2644-9.
- Longley DB, Harkin DP and Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. *Nat Rev Cancer* 3:330-8.
- Lostao MP, Mata JF, Larrayoz IM, Inzillo SM, Casado FJ and Pastor-Anglada M (2000) Electrogenic uptake of nucleosides and nucleoside-derived drugs by the human nucleoside transporter 1 (hCNT1) expressed in *Xenopus laevis* oocytes. *FEBS Lett* 481:137-40.
- Lotfi K, Mansson E, Peterson C, Eriksson S and Albertioni F (2002) Low level of mitochondrial deoxyguanosine kinase is the dominant factor in acquired resistance to 9-beta-D-arabinofuranosylguanine cytotoxicity. *Biochem Biophys Res Commun* 293:1489-96.

- Lu X, Gong S, Monks A, Zaharevitz D and Moscow JA (2002) Correlation of nucleoside and nucleobase transporter gene expression with antimetabolite drug cytotoxicity. *J Exp Ther Oncol* 2:200-12.
- Lum PY, Ngo LY, Bakken AH and Unadkat JD (2000) Human intestinal es nucleoside transporter: molecular characterization and nucleoside inhibitory profiles. *Cancer Chemother Pharmacol* 45:273-8.

M

- Mackey JR, Galmarini CM, Graham KA, Joy AA, Delmer A, Dabbagh L, Glubrecht D, Jewell LD, Lai R, Lang T, Hanson J, Young JD, Merle-Beral H, Binet JL, Cass CE and Dumontet C (2005) Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations. *Blood* 105:767-74.
- Mackey JR, Jennings LL, Clarke ML, Santos CL, Dabbagh L, Vsianska M, Koski SL, Coupland RW, Baldwin SA, Young JD and Cass CE (2002) Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. *Clin Cancer Res* 8:110-6.
- Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR and Cass CE (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. *Cancer Res* 58:4349-57.
- Mackey JR, Yao SY, Smith KM, Karpinski E, Baldwin SA, Cass CE and Young JD (1999) Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. *J Natl Cancer Inst* 91:1876-81.
- Mariadason JM, Arango D, Shi Q, Wilson AJ, Corner GA, Nicholas C, Aranes MJ, Lesser M, Schwartz EL and Augenlicht LH (2003) Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. *Cancer Res* 63:8791-812.
- Marzo I, Perez-Galan P, Giraldo P, Rubio-Felix D, Anel A and Naval J (2001) Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria. *Biochem J* 359:537-46.
- Mata JF, Garcia-Manteiga JM, Lostao MP, Fernandez-Veledo S, Guillen-Gomez E, Larrayoz IM, Lloberas J, Casado FJ and Pastor-Anglada M (2001) Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. *Mol Pharmacol* 59:1542-8.
- Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que TH and Catovsky D (1994) The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. *Leukemia* 8:1640-5.
- Maxwell PJ, Longley DB, Latif T, Boyer J, Allen W, Lynch M, McDermott U, Harkin DP, Allegra CJ and Johnston PG (2003) Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. *Cancer Res* 63:4602-6.
- McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D and Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. *J Clin Oncol* 16:2825-33.
- Melo JV, Brito-Babapulle V, Foroni L, Robinson DS, Luzzatto L and Catovsky D (1986) Two new cell lines from B-prolymphocytic leukaemia: characterization by morphology, immunological markers, karyotype and Ig gene rearrangement. *Int J Cancer* 38:531-8.
- Meckling-Gill KA, Guilbert L and Cass CE (1993) CSF-1 stimulates nucleoside transport in S1 macrophages. *J Cell Physiol* 155:530-8.
- Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. *Oncogene* 9:1799-805.
- Monni O, Oinonen R, Elonen E, Franssila K, Teerenhovi L, Joensuu H and Knuutila S (1998) Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma. *Genes Chromosomes Cancer* 21:298-307.

- Monni O, Zhu Y, Franssila K, Oinonen R, Hoglund P, Elonen E, Joensuu H and Knuutila S (1999) Molecular characterization of deletion at 11q22.1-23.3 in mantle cell lymphoma. *Br J Haematol* 104:665-71.
- Montserrat E (1997) Chronic lymphoproliferative disorders. *Curr Opin Oncol* 9:34-41.
- Moon C, Soria JC, Jang SJ, Lee J, Obaidul Hoque M, Sibony M, Trink B, Chang YS, Sidransky D and Mao L (2003) Involvement of aquaporins in colorectal carcinogenesis. *Oncogene* 22:6699-703.
- Morabito F, Filangeri M, Callea I, Sculli G, Callea V, Fracchiolla NS, Neri A and Brugiatielli M (1997) Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs. *Haematologica* 82:16-20.
- Moreau EJ, Matutes E, A'Hern RP, Morilla AM, Morilla RM, Owusu-Ankomah KA, Seon BK and Catovsky D (1997) Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). *Am J Clin Pathol* 108:378-82.
- Mosconi AM, Crino L and Tonato M (1997) Combination therapy with gemcitabine in non-small cell lung cancer. *Eur J Cancer* 33 Suppl 1:S14-7.
- Mosner J, Mummenbrauer T, Bauer C, Sczakiel G, Grosse F and Deppert W (1995) Negative feedback regulation of wild-type p53 biosynthesis. *Embo J* 14:4442-9.

N

- Nabhan C, Krett N, Gandhi V and Rosen S (2001) Gemcitabine in hematologic malignancies. *Curr Opin Oncol* 13:514-21.
- Neff T and Blau CA (1996) Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. *Exp Hematol* 24:1340-6.
- Newcomb EW, el Rouby S and Thomas A (1995) A unique spectrum of p53 mutations in B-cell chronic lymphocytic leukemia distinct from that of other lymphoid malignancies. *Mol Carcinog* 14:227-32.
- Nielsen SE, Munch-Petersen B and Mejer J (1995) Increased ratio between deoxycytidine kinase and thymidine kinase 2 in CLL lymphocytes compared to normal lymphocytes. *Leuk Res* 19:443-7.
- Nomura Y, Inanami O, Takahashi K, Matsuda A and Kuwabara M (2000) 2-Chloro-2'-deoxyadenosine induces apoptosis through the Fas/Fas ligand pathway in human leukemia cell line MOLT-4. *Leukemia* 14:299-306.

O

- O'Connor OA (2004) The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas. *Curr Treat Options Oncol* 5:269-81.
- Ohno Y, Spriggs D, Matsukage A, Ohno T and Kufe D (1988) Effects of 1-beta-D-arabinofuranosylcytosine incorporation on elongation of specific DNA sequences by DNA polymerase beta. *Cancer Res* 48:1494-8.
- Okamura S, Arakawa H, Tanaka T, Nakanishi H, Ng CC, Taya Y, Monden M and Nakamura Y (2001) p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. *Mol Cell* 8:85-94.
- Orr RM, Talbot DC, Aherne WG, Fisher TC, Serafinowski P and Harrap KR (1995) 2'-Deoxycytidine kinase deficiency is a major determinant of 2-chloro-2'-deoxyadenosine resistance in lymphoid cell lines. *Clin Cancer Res* 1:391-8.
- Osaki M, Tatebe S, Goto A, Hayashi H, Oshimura M and Ito H (1997) 5-Fluorouracil (5-FU) induced apoptosis in gastric cancer cell lines: role of the p53 gene. *Apoptosis* 2:221-6.
- Owen RP, Gray JH, Taylor TR, Carlson EJ, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE and Giacomini KM (2005) Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2. *Pharmacogenet Genomics* 15:83-90.

P

- Pajor AM and Wright EM (1992) Cloning and functional expression of a mammalian Na⁺/nucleoside cotransporter. A member of the SGLT family. *J Biol Chem* 267:3557-60.

- Park JS, Young Yoon S, Kim JM, Yeom YI, Kim YS and Kim NS (2004) Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. *Cancer Lett* 214:19-33.
- Parker WB, Shaddix SC, Rose LM, Shewach DS, Hertel LW, Secrist JA, 3rd, Montgomery JA and Bennett LL, Jr. (1999) Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-beta-D-ribofuranosyl)adenine in CEM cells. *Mol Pharmacol* 55:515-20.
- Pastor-Anglada M, Felipe A and Casado FJ (1998) Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies. *Trends Pharmacol Sci* 19:424-30.
- Patil SD, Ngo LY and Unadkat JD (2000) Structure-inhibitory profiles of nucleosides for the human intestinal N1 and N2 Na⁺-nucleoside transporters. *Cancer Chemother Pharmacol* 46:394-402.
- Pennycooke M, Chaudary N, Shuralyova I, Zhang Y and Coe IR (2001) Differential expression of human nucleoside transporters in normal and tumor tissue. *Biochem Biophys Res Commun* 280:951-9.
- Petak I, Tillman DM and Houghton JA (2000) p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines. *Clin Cancer Res* 6:4432-41.
- Petersen AJ, Brown RD, Gibson J, Pope B, Luo XF, Schutz L, Wiley JS and Joshua DE (1996) Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro. *Eur J Haematol* 56:213-20.
- Pettitt AR, Sherrington PD and Cawley JC (2000) Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues. *Cancer Res* 60:4187-93.
- Pinyol M, Cobo F, Bea S, Jares P, Nayach I, Fernandez PL, Montserrat E, Cardesa A and Campo E (1998) p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. *Blood* 91:2977-84.
- Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R and Gandhi V (1995) Gemcitabine: metabolism, mechanisms of action, and self-potential. *Semin Oncol* 22:3-10.
- Plunkett W, Liliemark JO, Estey E and Keating MJ (1987) Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. *Semin Oncol* 14:159-66.
- Plunkett W and Saunders PP (1991) Metabolism and action of purine nucleoside analogs. *Pharmacol Ther* 49:239-68.
- Polyak K, Xia Y, Zweier JL, Kinzler KW and Vogelstein B (1997) A model for p53-induced apoptosis. *Nature* 389:300-5.
- Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W, 3rd and Dantzig AH (2005) The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. *Mol Cancer Ther* 4:855-63.
- Pressacco J, Mitrovski B, Erlichman C and Hedley DW (1995a) Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. *Cancer Res* 55:1505-8.
- Pressacco J, Wiley JS, Jamieson GP, Erlichman C and Hedley DW (1995b) Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis. *Br J Cancer* 72:939-42.

R

- Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN and Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. *Blood* 46:219-34.
- Raphael B, Andersen JW, Silber R, Oken M, Moore D, Bennett J, Bonner H, Hahn R, Knospe WH, Mazza J and et al. (1991) Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. *J Clin Oncol* 9:770-6.
- Rauchwerger DR, Firby PS, Hedley DW and Moore MJ (2000) Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. *Cancer Res* 60:6075-9.

- Reed JC (1998) Molecular biology of chronic lymphocytic leukemia: implications for therapy. *Semin Hematol* 35:3-13.
- Reichard P (1988) Interactions between deoxyribonucleotide and DNA synthesis. *Annu Rev Biochem* 57:349-74.
- Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J and Borst P (2003) Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. *Mol Pharmacol* 63:1094-103.
- Reigner B, Watanabe T, Schuller J, Lucraft H, Sasaki Y, Bridgewater J, Saeki T, McAleer J, Kuranami M, Poole C, Kimura M, Monkhouse J, Yorulmaz C, Weidekamm E and Grange S (2003) Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. *Cancer Chemother Pharmacol* 52:193-201.
- Reiman T, Clarke ML, Dabbagh L, Vsianska M, Coupland RW, Belch AR, Baldwin SA, Young JD, Cass CE and Mackey JR (2002a) Differential expression of human equilibrative nucleoside transporter 1 (hENT1) protein in the Reed-Sternberg cells of Hodgkin's disease. *Leuk Lymphoma* 43:1435-40.
- Reiman T, Graham KA, Wong J, Belch AR, Coupland R, Young J, Cass CE and Mackey JR (2002b) Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case study. *Leukemia* 16:1886-7.
- Resta R, Yamashita Y and Thompson LF (1998) Ecto-enzyme and signaling functions of lymphocyte CD73. *Immunol Rev* 161:95-109.
- Ritzel MW, Ng AM, Yao SY, Graham K, Loewen SK, Smith KM, Hyde RJ, Karpinski E, Cass CE, Baldwin SA and Young JD (2001a) Recent molecular advances in studies of the concentrative Na⁺-dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). *Mol Membr Biol* 18:65-72.
- Ritzel MW, Ng AM, Yao SY, Graham K, Loewen SK, Smith KM, Ritzel RG, Mowles DA, Carpenter P, Chen XZ, Karpinski E, Hyde RJ, Baldwin SA, Cass CE and Young JD (2001b) Molecular identification and characterization of novel human and mouse concentrative Na⁺-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). *J Biol Chem* 276:2914-27.
- Ritzel MW, Yao SY, Huang MY, Elliott JF, Cass CE and Young JD (1997) Molecular cloning and functional expression of cDNAs encoding a human Na⁺-nucleoside cotransporter (hCNT1). *Am J Physiol* 272:C707-14.
- Ritzel MW, Yao SY, Ng AM, Mackey JR, Cass CE and Young JD (1998) Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na⁺/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. *Mol Membr Biol* 15:203-11.
- Robak T (2002) The role of nucleoside analogues in the treatment of chronic lymphocytic leukemia-lessons learned from prospective randomized trials. *Leuk Lymphoma* 43:537-48.
- Robak T (2004) Monoclonal antibodies in the treatment of chronic lymphoid leukemias. *Leuk Lymphoma* 45:205-19.
- Robak T and Kasznicki M (2002) Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. *Leukemia* 16:1015-27.
- Romaguera JE, Khouri IF, Kantarjian HM, Hagemester FB, Rodriguez MA, McLaughlin P, Sarris AH, Younes A, Rodriguez J and Cabanillas F (2000) Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. *Leuk Lymphoma* 39:77-85.
- Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur DC, Mitchell JB, Marti GE, Fowler DH, Wilson WH and Staudt LM (2004) Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. *Blood* 104:1428-34.
- Rozman C and Montserrat E (1995) Chronic lymphocytic leukemia. *N Engl J Med* 333:1052-7.
- Rudolph FB, Kulkarni AD, Schandle VB and Van Buren CT (1984) Involvement of dietary nucleotides in T lymphocyte function. *Adv Exp Med Biol* 165 Pt B:175-8.
- Ruiz van Haperen VW, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermsen M, Vermorcken JB, Pinedo HM and Peters GJ (1994) Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. *Cancer Res* 54:4138-43.

Ruiz van Haperen VW, Veerman G, Vermorken JB and Peters GJ (1993) 2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. *Biochem Pharmacol* 46:762-6.

S

- Sabini E, Ort S, Monnerjahn C, Konrad M and Lavie A (2003) Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. *Nat Struct Biol* 10:513-9.
- Saltman DL, Cachia PG, Dewar AE, Ross FM, Krajewski AS, Ludlam C and Steel CM (1988) Characterization of a new non-Hodgkin's lymphoma cell line (NCEB-1) with a chromosomal (11:14) translocation [t(11:14)(q13;q32)]. *Blood* 72:2026-30.
- Sampath D, Rao VA and Plunkett W (2003) Mechanisms of apoptosis induction by nucleoside analogs. *Oncogene* 22:9063-74.
- Sampol A, Rodriguez J, Galmes B, Gutierrez A and Besalduch J (2004) Gemcitabine and oxaliplatin: an effective regimen in a patient with progressive refractory mantle cell lymphoma. *Leuk Lymphoma* 45:1289-91.
- Santi DV, McHenry CS and Sommer H (1974) Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. *Biochemistry* 13:471-81.
- Sarkar M, Han T, Damaraju V, Carpenter P, Cass CE and Agarwal RP (2005) Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells. *Biochem Pharmacol* 70:426-32.
- Sasvari-Szekely M, Csapo Z, Spasokoukotskaja T, Eriksson S and Staub M (1998) Activation of deoxycytidine kinase during inhibition of DNA synthesis in human lymphocytes. *Adv Exp Med Biol* 431:519-23.
- Savage DG, Cohen NS, Hesdorffer CS, Heitjan D, Oster MW, Garrett TJ, Bar M, del Prete S, March R, Lonberg M, Talbot S, Mears JG, Flamm M, Taub RN and Nichols G (2003) Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. *Leuk Lymphoma* 44:477-81.
- Schaner ME, Wang J, Zevin S, Gerstin KM and Giacomini KM (1997) Transient expression of a purine-selective nucleoside transporter (SPNTint) in a human cell line (HeLa). *Pharm Res* 14:1316-21.
- Schaner ME, Wang J, Zhang L, Su SF, Gerstin KM and Giacomini KM (1999) Functional characterization of a human purine-selective, Na⁺-dependent nucleoside transporter (hSPNT1) in a mammalian expression system. *J Pharmacol Exp Ther* 289:1487-91.
- Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO and Weinstein JN (2000) A gene expression database for the molecular pharmacology of cancer. *Nat Genet* 24:236-44.
- Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A and Fridland A (1999) MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. *Nat Med* 5:1048-51.
- Sen RP, Sobrevia L, Delicado EG, Yudilevich D and Miras-Portugal MT (1996) Bovine adrenal endothelial cells express nucleoside transporters nonregulated by protein kinases A and C. *Am J Physiol* 271:C504-10.
- Seve P, Mackey JR, Isaac S, Tredan O, Souquet PJ, Perol M, Cass C and Dumontet C (2005) cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. *Lung Cancer* 49:363-70.
- Sherley JL and Kelly TJ (1988) Regulation of human thymidine kinase during the cell cycle. *J Biol Chem* 263:8350-8.
- Shewach DS and Mitchell BS (1986) Characterization of arabinosylguanine resistance in a lymphoblastoid cell line. *Adv Exp Med Biol* 195 Pt B:605-9.
- Simstein R, Burow M, Parker A, Weldon C and Beckman B (2003) Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. *Exp Biol Med* (Maywood) 228:995-1003.
- Sjoberg AH, Wang L and Eriksson S (1998) Substrate specificity of human recombinant mitochondrial deoxyguanosine kinase with cytostatic and antiviral purine and pyrimidine analogs. *Mol Pharmacol* 53:270-3.

- Smid K, Van Moorsel CJ, Noordhuis P, Voorn DA and Peters GJ (2001) Interference of gemcitabine triphosphate with the measurements of deoxynucleotides using an optimized DNA polymerase elongation assay. *Int J Oncol* 19:157-62.
- Smith CL, Pilarski LM, Egerton ML and Wiley JS (1989) Nucleoside transport and proliferative rate in human thymocytes and lymphocytes. *Blood* 74:2038-42.
- Smith KM, Ng AM, Yao SY, Labeledz KA, Knaus EE, Wiebe LI, Cass CE, Baldwin SA, Chen XZ, Karpinski E and Young JD (2004) Electrophysiological characterization of a recombinant human Na⁺-coupled nucleoside transporter (hCNT1) produced in *Xenopus* oocytes. *J Physiol* 558:807-23.
- Sobrero AF, Moir RD, Bertino JR and Handschumacher RE (1985) Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2'-deoxyuridine in the HCT-8 human carcinoma line. *Cancer Res* 45:3155-60.
- Soler C, Felipe A, Casado FJ, Celada A and Pastor-Anglada M (2000) Nitric oxide regulates nucleoside transport in activated B lymphocytes. *J Leukoc Biol* 67:345-9.
- Soler C, Felipe A, Garcia-Manteiga J, Serra M, Guillen-Gomez E, Casado FJ, MacLeod C, Modolell M, Pastor-Anglada M and Celada A (2003) Interferon-gamma regulates nucleoside transport systems in macrophages through signal transduction and activator of transduction factor 1 (STAT1)-dependent and -independent signalling pathways. *Biochem J* 375:777-83.
- Soler C, Felipe A, Mata JF, Casado FJ, Celada A and Pastor-Anglada M (1998) Regulation of nucleoside transport by lipopolysaccharide, phorbol esters, and tumor necrosis factor-alpha in human B-lymphocytes. *J Biol Chem* 273:26939-45.
- Soler C, Garcia-Manteiga J, Valdes R, Xaus J, Comalada M, Casado FJ, Pastor-Anglada M, Celada A and Felipe A (2001a) Macrophages require different nucleoside transport systems for proliferation and activation. *Faseb J* 15:1979-88.
- Soler C, Valdes R, Garcia-Manteiga J, Xaus J, Comalada M, Casado FJ, Modolell M, Nicholson B, MacLeod C, Felipe A, Celada A and Pastor-Anglada M (2001b) Lipopolysaccharide-induced apoptosis of macrophages determines the up-regulation of concentrative nucleoside transporters Cnt1 and Cnt2 through tumor necrosis factor-alpha-dependent and -independent mechanisms. *J Biol Chem* 276:30043-9.
- Spasokoukotskaja T, Arner ES, Brosjo O, Gunven P, Juliusson G, Liliemark J and Eriksson S (1995) Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. *Eur J Cancer* 31A:202-8.
- Spasokoukotskaja T, Sasvari-Szekely M, Hullan L, Albertioni F, Eriksson S and Staub M (1998) Activation of deoxycytidine kinase by various nucleoside analogues. *Adv Exp Med Biol* 431:641-5.
- Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R and Mackey JR (2004) The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. *Clin Cancer Res* 10:6956-61.
- Spychala J, Madrid-Marina V and Fox IH (1989) Evidence for "low Km" and "high Km" soluble 5'-nucleotidases in human tissues and rat liver. *Adv Exp Med Biol* 253B:129-34.
- Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P, Janka-Schaub GE, Armstrong SA, Korsmeyer SJ and Pieters R (2003) Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. *Blood* 101:1270-6.
- Stankovic T, Weber P, Stewart G, Bedenham T, Murray J, Byrd PJ, Moss PA and Taylor AM (1999) Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. *Lancet* 353:26-9.
- Stegmann AP, Honders MW, Kester MG, Landegent JE and Willemze R (1993) Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine. *Leukemia* 7:1005-11.
- Stoetzer OJ, Pogrebniak A, Scholz M, Pelka-Fleischer R, Gullis E, Darsow M, Nussler V and Wilmanns W (1999) Drug-induced apoptosis in chronic lymphocytic leukemia. *Leukemia* 13:1873-80.
- Sundaram M, Yao SY, Ng AM, Cass CE, Baldwin SA and Young JD (2001) Equilibrative nucleoside transporters: mapping regions of interaction for the substrate analogue nitrobenzylthioinosine (NBMPR) using rat chimeric proteins. *Biochemistry* 40:8146-51.

Sundaram M, Yao SY, Ng AM, Griffiths M, Cass CE, Baldwin SA and Young JD (1998) Chimeric constructs between human and rat equilibrative nucleoside transporters (hENT1 and rENT1) reveal hENT1 structural domains interacting with coronary vasoactive drugs. *J Biol Chem* 273:21519-25.

T

Tattersall MH, Slowiaczek P and De Fazio A (1983) Regional variation in human extracellular purine levels. *J Lab Clin Med* 102:411-20.

Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M and Newcomb EW (1996) Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. *Oncogene* 12:1055-62.

Troester MA, Hoadley KA, Sorlie T, Herbert BS, Borresen-Dale AL, Lonning PE, Shay JW, Kaufmann WK and Perou CM (2004) Cell-type-specific responses to chemotherapeutics in breast cancer. *Cancer Res* 64:4218-26.

Tse CM, Belt JA, Jarvis SM, Paterson AR, Wu JS and Young JD (1985) Reconstitution studies of the human erythrocyte nucleoside transporter. *J Biol Chem* 260:3506-11.

Tseng WC, Derse D, Cheng YC, Brockman RW and Bennett LL, Jr. (1982) In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. *Mol Pharmacol* 21:474-7.

Tsujimoto Y, Finger LR, Yunis J, Nowell PC and Croce CM (1984a) Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. *Science* 226:1097-9.

Tsujimoto Y, Yunis J, Onorato-Showe L, Erikson J, Nowell PC and Croce CM (1984b) Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. *Science* 224:1403-6.

V

Valdes R, Casado FJ and Pastor-Anglada M (2002) Cell-cycle-dependent regulation of CNT1, a concentrative nucleoside transporter involved in the uptake of cell-cycle-dependent nucleoside-derived anticancer drugs. *Biochem Biophys Res Commun* 296:575-9.

Valdes R, Ortega MA, Casado FJ, Felipe A, Gil A, Sanchez-Pozo A and Pastor-Anglada M (2000) Nutritional regulation of nucleoside transporter expression in rat small intestine. *Gastroenterology* 119:1623-30.

Vaquerizas JM, Dopazo J and Diaz-Uriarte R (2004) DNMAID: web-based diagnosis and normalization for microarray data. *Bioinformatics* 20:3656-8.

Verhoef V, Sarup J and Fridland A (1981) Identification of the mechanism of activation of 9-beta-D-arabinofuranosyladenine in human lymphoid cells using mutants deficient in nucleoside kinases. *Cancer Res* 41:4478-83.

Veuger MJ, Honders MW, Willemze R and Barge RM (2002) Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia. *Eur J Haematol* 69:171-8.

W

Wang J and Giacomini KM (1997) Molecular determinants of substrate selectivity in Na⁺-dependent nucleoside transporters. *J Biol Chem* 272:28845-8.

Wang J and Giacomini KM (1999a) Characterization of a bioengineered chimeric Na⁺-nucleoside transporter. *Mol Pharmacol* 55:234-40.

Wang J and Giacomini KM (1999b) Serine 318 is essential for the pyrimidine selectivity of the N2 Na⁺-nucleoside transporter. *J Biol Chem* 274:2298-302.

Wang J, Schaner ME, Thomassen S, Su SF, Piquette-Miller M and Giacomini KM (1997a) Functional and molecular characteristics of Na⁽⁺⁾-dependent nucleoside transporters. *Pharm Res* 14:1524-32.

- Wang J, Su SF, Dresser MJ, Schaner ME, Washington CB and Giacomini KM (1997b) Na(+)-dependent purine nucleoside transporter from human kidney: cloning and functional characterization. *Am J Physiol* 273:F1058-65.
- Wang L, Karlsson A, Arner ES and Eriksson S (1993) Substrate specificity of mitochondrial 2'-deoxyguanosine kinase. Efficient phosphorylation of 2-chlorodeoxyadenosine. *J Biol Chem* 268:22847-52.
- Wang L, Munch-Petersen B, Herrstrom Sjöberg A, Hellman U, Bergman T, Jornvall H and Eriksson S (1999) Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates. *FEBS Lett* 443:170-4.
- Ward JL, Sherali A, Mo ZP and Tse CM (2000) Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. ENT2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine. *J Biol Chem* 275:8375-81.
- Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P and Fenaux P (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. *Blood* 84:3148-57.
- Wiley JS, Cebon JS, Jamieson GP, Szer J, Gibson J, Woodruff RK, McKendrick JJ, Sheridan WP, Biggs JC, Snook MB and et al. (1994) Assessment of proliferative responses to granulocyte-macrophage colony-stimulating factor (GM-CSF) in acute myeloid leukaemia using a fluorescent ligand for the nucleoside transporter. *Leukemia* 8:181-5.
- Wiley JS, Jones SP and Sawyer WH (1983) Cytosine arabinoside transport by human leukaemic cells. *Eur J Cancer Clin Oncol* 19:1067-74.
- Wiley JS, Jones SP, Sawyer WH and Paterson AR (1982) Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. *J Clin Invest* 69:479-89.
- Wiley JS, Snook MB and Jamieson GP (1989) Nucleoside transport in acute leukaemia and lymphoma: close relation to proliferative rate. *Br J Haematol* 71:203-7.
- Wohlhueter RM, Mclvor RS and Plagemann PG (1980) Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. *J Cell Physiol* 104:309-19.
- Wright AM, Paterson AR, Sowa B, Akabutu JJ, Grundy PE and Gati WP (2002) Cytotoxicity of 2-chlorodeoxyadenosine and arabinosylcytosine in leukaemic lymphoblasts from paediatric patients: significance of cellular nucleoside transporter content. *Br J Haematol* 116:528-37.
- Wu X, Yuan G, Brett CM, Hui AC and Giacomini KM (1992) Sodium-dependent nucleoside transport in choroid plexus from rabbit. Evidence for a single transporter for purine and pyrimidine nucleosides. *J Biol Chem* 267:8813-8.

Y

- Yao SY, Ng AM, Muzyka WR, Griffiths M, Cass CE, Baldwin SA and Young JD (1997) Molecular cloning and functional characterization of nitrobenzylthioinosine (NBMPR)-sensitive (es) and NBMPR-insensitive (ei) equilibrative nucleoside transporter proteins (rENT1 and rENT2) from rat tissues. *J Biol Chem* 272:28423-30.
- Yao SY, Ng AM, Sundaram M, Cass CE, Baldwin SA and Young JD (2001) Transport of antiviral 3'-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in *Xenopus* oocytes. *Mol Membr Biol* 18:161-7.
- Yao SY, Ng AM, Vickers MF, Sundaram M, Cass CE, Baldwin SA and Young JD (2002) Functional and molecular characterization of nucleobase transport by recombinant human and rat equilibrative nucleoside transporters 1 and 2. Chimeric constructs reveal a role for the ENT2 helix 5-6 region in nucleobase translocation. *J Biol Chem* 277:24938-48.
- Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T and Hashimoto-Tamaoki T (2001) Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. *Cancer Res* 61:1029-37.

Z

- Zaja F, Di Loreto C, Amoroso V, Salmaso F, Russo D, Silvestri F, Fanin R, Damiani D, Infanti L, Mariuzzi L, Beltrami CA and Baccarani M (1998) BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine. *Leuk Lymphoma* 28:567-72.
- Zhang J, Visser F, Vickers MF, Lang T, Robins MJ, Nielsen LP, Nowak I, Baldwin SA, Young JD and Cass CE (2003) Uridine binding motifs of human concentrative nucleoside transporters 1 and 3 produced in *Saccharomyces cerevisiae*. *Mol Pharmacol* 64:1512-20.
- Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH and Levine AJ (2000) Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. *Genes Dev* 14:981-93.
- Zheng X and Chen X (2001) Aquaporin 3, a glycerol and water transporter, is regulated by p73 of the p53 family. *FEBS Lett* 489:4-7.

PUBLICACIONES

A partir d'aquesta tesi s'han derivat les següents publicacions:

- Molina-Arcas M, Bellosillo B, Casado FJ, Montserrat E, Gil J, Colomer D and Pastor-Anglada M (2003) *Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia*. Blood 101:2328-34.
- Molina-Arcas M, Marce S, Villamor N, Huber-Ruano I, Casado FJ, Bellosillo B, Montserrat E, Gil J, Colomer D and Pastor-Anglada M (2005) *Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells*. Leukemia 19:64-8.
- Marcé S, Molina-Arcas M, Villamor N, Casado FJ, Campo E, Pastor-Anglada M, Colomer D. *Role of equilibrative nucleoside transporters (ENT) in mantle cell lymphoma cells*. Enviat
- Molina-Arcas M, Moreno-Bueno G, Hernández-Vargas H, Casado FJ, Palacios J, Pastor-Anglada M. *Transcriptomic analysis of the hENT1-mediated action of the nucleoside derived drug 5'-DFUR in breast cancer MCF7 cells*. Enviat
- Pastor-Anglada M, Casado FJ, Valdes R, Mata J, Garcia-Manteiga J and Molina M (2001) *Complex regulation of nucleoside transporter expression in epithelial and immune system cells*. Mol Membr Biol 18:81-5.
- Pastor-Anglada M, Molina-Arcas M, Casado FJ, Bellosillo B, Colomer D and Gil J (2004) *Nucleoside transporters in chronic lymphocytic leukaemia*. Leukemia 18:385-93.

Altres publicacions:

- Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A and Pastor-Anglada M (2003) *Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity*. Clin Cancer Res 9:5000-8.
- Cano-Soldado P, Larrayoz IM, Molina-Arcas M, Casado FJ, Martinez-Picado J, Lostao MP and Pastor-Anglada M (2004) *Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1)*. Antivir Ther 9:993-1002.
- Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M, Lostao MP, Larrayoz I, Martinez-Picado J and Casado FJ (2005) *Cell entry and export of nucleoside analogues*. Virus Res 107:151-64.

